10:39 AM EST, 12/19/2024 (MT Newswires) -- Ocugen ( OCGN ) said Thursday the Data and Safety Monitoring Board approved the continuation of its phase 1/2 trial for OCU410, a gene therapy for geographic atrophy secondary to dry age-related macular degeneration.

Initial phase 2 data showed OCU410 is safe and well-tolerated, with no serious adverse events reported, the company said.

Ocugen ( OCGN ) said dosing will conclude in early 2025, Ocugen ( OCGN ) said.